Azura Ophthalmics is pioneering the development of a new class of ophthalmic therapeutics known as keratolytics, specifically targeting conditions related to the ocular surface, such as Meibomian Gland Dysfunction (MGD) and Contact Lens Discomfort (CLD). Their lead product, AZR-MD-001, utilizes selenium sulfide in an ophthalmic ointment formulation designed to address the underlying pathophysiology of MGD. This innovative treatment aims to break down abnormal keratin aggregates that obstruct meibomian glands, thereby improving meibum quality and flow. By addressing the root causes of these conditions, Azura seeks to alleviate symptoms such as dryness, irritation, and inflammation, which are prevalent among patients suffering from MGD and CLD.

The company's approach combines insights from both ophthalmology and dermatology, leveraging their understanding of keratolytic agents to create effective therapies for underserved ocular indications. Azura's extensive pipeline includes over 250 internally discovered new chemical entities that target a wide range of ocular surface diseases. Their research emphasizes a multi-modal mechanism of action, which not only aims to restore gland function but also enhances the overall health of the ocular surface. By focusing on the unmet needs in ocular health, Azura Ophthalmics is positioned to make significant advancements in the treatment of chronic eye conditions that have long been inadequately addressed.

Israel

Azura Ophthalmics is utilizing our deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of Ophthalmic Keratolytics to treat underserved ophthalmic conditions.

Our differentiated approach combines ophthalmologic and dermatologic solutions to harness the unique properties of keratolytics to treat the root cause of numerous underserved ocular indications.

Our internally discovered pipeline of new chemical entities allows us to develop a portfolio of first-in-class ophthalmic therapeutics for significant unmet needs.

Azura Ophthalmics

Company Details